Japanese warnings for fingolimod revised on cardiac safety concerns
This article was originally published in Scrip
Japan's ministry of health, labour and welfare has ordered revisions to the warnings and basic precautions for the multiple sclerosis drug fingolimod after reviewing reports of cardiac problems in other markets.
You may also be interested in...
This time we touch on Pfizer’s R&D plans, real-world evidence for coronavirus vaccines, a new approval in lung cancer, challenges for Galapagos, and Takeda's pipeline story.
Japanese major links with new partners in European consortium to progress first-in-class molecule for multiple hematological malignancies.
A resolution in a long-running patent dispute, expansion of coronavirus vaccine production, drug development trends over the past decade, hematological malignancies in a clinical trial, and the last instalment in the Scrip Asks series all feature in this week's podcast version of Scrip's Five Must-Know Things.